))
Belzutifan: Primary Tx for Bilat Juxtapapillary Retinal Hemangioblastoma in VHL Patient
Manage episode 492261266 series 3494608
Content provided by American Society of Retina Specialists (ASRS). All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by American Society of Retina Specialists (ASRS) or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
On this episode of the JVRD Author's Forum podcast, Dr. Nikhil Batra of the Dartmouth School of Medicine discusses "Belzutifan as the Primary Treatment of Bilateral Juxtapapillary Retinal Hemangioblastoma in a Patient With von Hippel–Lindau Disease," published in the May/June 2025 issue of JVRD.
Host Dr. Timothy Murray and Dr. Batra discuss how belzutifan, a HIF-2α inhibitor, was used off-label to successfully treat bilateral optic nerve hemangioblastomas in a patient with Von Hippel-Lindau Disease, resulting in significant tumor regression and visual improvement. Hear how this targeted therapy may represent a promising new direction in managing complex retinal tumors that are difficult to treat with traditional approaches.
42 episodes
Share
